Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Inclusion Criteria: * Histologically confirmed\* endometrial epithelial carcinoma, including any of the following cell types: * Endometrioid adenocarcinoma * Serous adenocarcinoma * Undifferentiated carcinoma * Clear cell adenocarcinoma * Mixed epithelial carcinoma * Adenocarcinoma not otherwise specified * Mucinous adenocarcinoma * Squamous cell carcinoma * Transitional cell carcinoma * Mesonephric carcinoma * Recurrent or persistent disease that is refractory to curative therapy or established treatments * Measurable disease, defined as ≥ 1 lesion that can be measured in ≥ 1 dimension (longest dimension to be recorded) * Each lesion must be ≥ 20 mm when measured by conventional techniques (palpation, plain x-ray, CT scan, or MRI) OR ≥ 10 mm when measured by spiral CT scan * Must have ≥ 1 target lesion to be used to assess response, as defined by RECIST criteria * Tumors within a previously irradiated field are designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence ≥ 90 days following completion of radiotherapy * Must have received 1 prior chemotherapeutic regimen for the management of endometrial carcinoma * Chemotherapy administered as a radiosensitizer in conjunction with primary radiotherapy is considered a systemic chemotherapy regimen * Not eligible for a higher priority GOG protocol, if one exists (e.g., any active phase III GOG protocol for the same patient population) * No pri…